{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T20:29:00Z","timestamp":1780950540803,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005716","name":"Babol University of Medical Sciences","doi-asserted-by":"publisher","award":["140012729"],"award-info":[{"award-number":["140012729"]}],"id":[{"id":"10.13039\/501100005716","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.micpath.2023.106206","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T08:53:46Z","timestamp":1686905626000},"page":"106206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Efficacy of clofazimine against acute and chronic Toxoplasma gondii infection in mice"],"prefix":"10.1016","volume":"181","author":[{"given":"Nooshin","family":"Biglari-Moghadam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Najafzadehvarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6017-836X","authenticated-orcid":false,"given":"Tahmineh","family":"Gorgani-Firouzjaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Ghasemi-Kasman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.micpath.2023.106206_bib1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/CMR.11.2.267","article-title":"Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts","volume":"11","author":"Dubey","year":"1998","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.micpath.2023.106206_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.exppara.2015.06.005","article-title":"Could miltefosine be used as a therapy for toxoplasmosis?","volume":"157","author":"Eissa","year":"2015","journal-title":"Exp. Parasitol."},{"issue":"4","key":"10.1016\/j.micpath.2023.106206_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.puhe.2007.08.009","article-title":"Congenital toxoplasmosis: priorities for further health promotion action","volume":"122","author":"Elsheikha","year":"2008","journal-title":"Publ. Health"},{"key":"10.1016\/j.micpath.2023.106206_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.actatropica.2019.04.013","article-title":"Evaluation of nitazoxanide as a novel drug for the treatment of acute and chronic toxoplasmosis","volume":"195","author":"El-Kowrany","year":"2019","journal-title":"Acta Trop."},{"key":"10.1016\/j.micpath.2023.106206_bib5","series-title":"Handbook of Clinical Neurology","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/B978-0-444-53490-3.00008-X","article-title":"Chapter 8 - toxoplasmosis","author":"Halonen","year":"2013"},{"key":"10.1016\/j.micpath.2023.106206_bib6","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/S0140-6736(04)16412-X","volume":"363","author":"Montoya","year":"2004","journal-title":"Toxoplasmosis, The Lancet"},{"issue":"10","key":"10.1016\/j.micpath.2023.106206_bib7","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1007\/s00436-018-6027-z","article-title":"Activities of anti-Toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review","volume":"117","author":"Montazeri","year":"2018","journal-title":"Parasitol. Res."},{"issue":"2","key":"10.1016\/j.micpath.2023.106206_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijpddr.2014.02.002","article-title":"Drug repurposing and human parasitic protozoan diseases","volume":"4","author":"Andrews","year":"2014","journal-title":"Int. J. Parasitol. Drugs. Drug. Resist."},{"key":"10.1016\/j.micpath.2023.106206_bib9","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.biopha.2018.06.023","article-title":"Clofazimine: a useful antibiotic for drug-resistant tuberculosis","volume":"105","author":"Mirnejad","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.micpath.2023.106206_bib10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2217\/fmb-2019-0231","article-title":"Clofazimine: an old drug for never-ending diseases","volume":"15","author":"Riccardi","year":"2020","journal-title":"Future Microbiol."},{"issue":"5","key":"10.1016\/j.micpath.2023.106206_bib11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/00034983.1989.11812371","article-title":"Antileishmanial effects of clofazimine and other antimycobacterial agents","volume":"83","author":"Evans","year":"1989","journal-title":"Ann. Trop. Med. Parasitol."},{"issue":"5","key":"10.1016\/j.micpath.2023.106206_bib12","first-page":"2739","article-title":"Clofazimine inhibits the growth of Babesia and Theileria parasites in vitro and in vivo, antimicrob. Agents","volume":"60","author":"Tuvshintulga","year":"2016","journal-title":"Chemother"},{"issue":"1","key":"10.1016\/j.micpath.2023.106206_bib13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4314\/ahs.v17i1.24","article-title":"In vitro investigation of clofazimine analogues for antiplasmodial, cytotoxic and pro-oxidative activities","volume":"17","author":"Makgatho","year":"2017","journal-title":"Afr. Health Sci."},{"issue":"2","key":"10.1016\/j.micpath.2023.106206_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/cid\/ciaa421","article-title":"Clofazimine for treatment of cryptosporidiosis in human immunodeficiency virus infected adults: an experimental medicine, randomized, double-blind, placebo-controlled phase 2a trial","volume":"73","author":"Iroh Tam","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.micpath.2023.106206_bib15","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1021\/acsanm.8b00234","article-title":"Rapid recovery of clofazimine-loaded nanoparticles with long-term storage stability as anti-cryptosporidium therapy","volume":"1","author":"Feng","year":"2018","journal-title":"ACS Appl. Nano Mater."},{"issue":"10","key":"10.1016\/j.micpath.2023.106206_bib16","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1021\/acs.molpharmaceut.7b00521","article-title":"Design and solidification of fast-releasing clofazimine nanoparticles for treatment of cryptosporidiosis","volume":"14","author":"Zhang","year":"2017","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.micpath.2023.106206_bib17","first-page":"62","article-title":"Development of a Cx46 targeting strategy for cancer stem cells, Cell","volume":"27","author":"Mulkearns-Hubert","year":"2018","journal-title":"Rep"},{"issue":"10","key":"10.1016\/j.micpath.2023.106206_bib18","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/jnr.24036","article-title":"Contribution of dopamine neurotransmission in proconvulsant effect of Toxoplasma gondii infection in male mice","volume":"95","author":"Babaie","year":"2017","journal-title":"J. Neurosci. Res."},{"issue":"9","key":"10.1016\/j.micpath.2023.106206_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025259","article-title":"MIF participates in Toxoplasma gondii-induced pathology following oral infection","volume":"6","author":"Cavalcanti","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.micpath.2023.106206_bib20","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijantimicag.2004.09.015","article-title":"Effectiveness of spiramycin in murine models of acute and chronic toxoplasmosis","volume":"25","author":"Gruji\u0107","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.micpath.2023.106206_bib21","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41586-021-03431-4","article-title":"Clofazimine broadly inhibits coronaviruses including SARS-CoV-2","volume":"593","author":"Yuan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.micpath.2023.106206_bib22","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1128\/AAC.05183-11","article-title":"Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis","volume":"56","author":"Chew","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2023.106206_bib23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neuroscience.2015.10.013","article-title":"Enhanced remyelination following lysolecithin-induced demyelination in mice under treatment with fingolimod (FTY720)","volume":"311","author":"Yazdi","year":"2015","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.micpath.2023.106206_bib24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00436-015-4759-6","article-title":"Effect of Nigella sativa oil on experimental toxoplasmosis","volume":"115","author":"Mady","year":"2016","journal-title":"Parasitol. Res."},{"issue":"2","key":"10.1016\/j.micpath.2023.106206_bib25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0003-2697(79)90738-3","article-title":"Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction","volume":"95","author":"Ohkawa","year":"1979","journal-title":"Anal. Biochem."},{"issue":"7","key":"10.1016\/j.micpath.2023.106206_bib26","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/jac\/dkr147","article-title":"Failure of conventional treatment with pyrimethamine and sulfadiazine for secondary prophylaxis of cerebral toxoplasmosis in a patient with AIDS","volume":"66","author":"Faucher","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.micpath.2023.106206_bib27","first-page":"68","article-title":"Patterns of sulfadiazine acute nephrotoxicity","volume":"54","author":"Crespo","year":"2000","journal-title":"Clin. Nephrol."},{"issue":"2","key":"10.1016\/j.micpath.2023.106206_bib28","first-page":"318","article-title":"The riminophenazine agents clofazimine and B669 inhibit the proliferation of cancer cell lines in vitro by phospholipase A2-mediated oxidative and nonoxidative mechanisms","volume":"53","author":"Van Rensburg","year":"1993","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.micpath.2023.106206_bib29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bmc.2014.11.028","article-title":"Clofazimine analogs with antileishmanial and antiplasmodial activity","volume":"23","author":"Barteselli","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.micpath.2023.106206_bib30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.arcmed.2013.07.002","article-title":"Effect of nitaxozanide and pyrimethamine on astrocytes infected by Toxoplasma gondii in vitro","volume":"44","author":"Galv\u00e1n-Ram\u00edrez","year":"2013","journal-title":"Arch. Med. Res."},{"issue":"6","key":"10.1016\/j.micpath.2023.106206_bib31","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1128\/EC.00381-08","article-title":"Type II NADH dehydrogenase inhibitor 1-hydroxy-2-dodecyl-4(1H)quinolone leads to collapse of mitochondrial inner-membrane potential and ATP depletion in Toxoplasma gondii","volume":"8","author":"Lin","year":"2009","journal-title":"Eukaryot. Cell"},{"issue":"2","key":"10.1016\/j.micpath.2023.106206_bib32","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/jac\/dkw426","article-title":"Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline","volume":"72","author":"Cholo","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.micpath.2023.106206_bib33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1600-065X.2010.00992.x","article-title":"Immunology of Toxoplasma gondii","volume":"240","author":"Munoz","year":"2011","journal-title":"Immunol. Rev."},{"issue":"12","key":"10.1016\/j.micpath.2023.106206_bib34","article-title":"Clofazimine modulates the expression of lipid metabolism proteins in Mycobacterium leprae-infected macrophages","volume":"6","author":"Yang","year":"2012","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"6","key":"10.1016\/j.micpath.2023.106206_bib35","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jac\/dkf251","article-title":"Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii","volume":"50","author":"Djurkovi\u0107-Djakovi\u0107","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.micpath.2023.106206_bib36","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijantimicag.2004.09.015","article-title":"Effectiveness of spiramycin in murine models of acute and chronic toxoplasmosis","volume":"25","author":"Grujic","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"4","key":"10.1016\/j.micpath.2023.106206_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5455\/IJMRCR.total-antioxidant-capacity-multibacillary-type-leprocy","article-title":"Comparison of total antioxidant capacity (TAC) in the multibacillary (MB) type of leprosy patients before and after 3 Months of MDT-MB WHO therapy","volume":"2","author":"Kusuma","year":"2018","journal-title":"Int. J. Med. Rev. Case. Rep."}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401023002395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401023002395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T06:34:52Z","timestamp":1736404492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401023002395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":37,"alternative-id":["S0882401023002395"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2023.106206","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of clofazimine against acute and chronic Toxoplasma gondii infection in mice","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2023.106206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106206"}}